ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Nov 25, 2025
ARWR$49.24-15.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
INDEX TO FINANCIAL STATEMENTS AND SCHEDULES
INDEX TO FINANCIAL STATEMENTS AND SCHEDULE
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 185) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm | F-5 |
| Consolidated Balance Sheets as of September 30, 2025 and 2024 | F-6 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended September 30, 2025, 2024 and 2023 | F-7 |
| Consolidated Statements of Stockholders’ Equity for the years ended September 30, 2025, 2024 and 2023 | F-8 |
| Consolidated Statements of Cash Flows for the years ended September 30, 2025, 2024 and 2023 | F-9 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.